Source comparison
TB-500 Receptor Pharmacology: Peptide Comparison
This table compares TB-500 to structurally related peptides that also modulate actin dynamics or angiogenic pathways, highlighting key pharmacological distinctions. TB-500 (Thymosin Beta-4 fragment) Actin monomer sequestration; suspected GPCR activation Yes (K
This comparison does not assign a generated winner or score.
- This table compares TB-500 to structurally related peptides that also modulate actin dynamics or angiogenic pathways, highlighting key pharmacological distinctions.
- TB-500 (Thymosin Beta-4 fragment)
- Actin monomer sequestration; suspected GPCR activation
- Yes (Kd ~0.5–2.0 µM)
- 2–3 hours (plasma); 24–48 hours (tissue)
- Baseline (100%)
- Gold standard for actin-mediated migration; well-characterized in tissue repair models
- BPC-157
- Cytoprotection via nitric oxide pathway; FAK activation
- No
- 4–6 hours
- 40–60% (indirect via VEGF stabilization)
- Complementary to TB-500; no direct actin interaction but synergistic in wound healing
- GHK-Cu (Copper peptide)
- Collagen synthesis; MMP modulation
- 1–2 hours
- 30–50% (via TGF-β1 upregulation)
- Primarily extracellular matrix remodeling; does not influence cytoskeletal dynamics
- Thymosin Alpha-1
- Immune modulation (T-cell differentiation)
- 2–3 hours
- Negligible
- No direct angiogenic or actin-related function; distinct therapeutic niche
- VEGF-A (recombinant protein)
- Direct VEGFR2 activation
- 30–90 minutes
- 150–200% (direct receptor agonism)
- More potent angiogenic signal but no migration-enhancing actin effects; systemic side effects limit use
- TB-500's combination of actin sequestration and indirect VEGF upregulation makes it uniquely suited for tissue repair applications where both cell migration and vascularization are required. Peptides like BPC-157 work synergistically with TB-500 but do not replicate its cytoskeletal effects. VEGF-A surpasses TB-500 in pure angiogenic potency but lacks the migration-enhancing and cytoprotective actin-binding mechanism that makes TB-500 effective across multiple cell types (fibroblasts, keratinocytes, cardiomyocytes, endothelial cells).